Controversies in tuberculous infection among pediatric infectious disease specialists in North America

A. T. Cruz, A. L. Hersh, J. R. Starke, S. E. Beekmann, P. M. Polgreen, R. Banerjee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate the extent to which advancements in the diagnosis and treatment of latent tuberculous infection (LTBI) have been integrated into practice by pediatric infectious disease (PID) specialists. DESIGN: We conducted an online survey of the Infectious Diseases Society of America's Emerging Infections Network (EIN) membership. RESULTS: Of the 323 members, 197 (61%) responded: 7% cared for ≥5 children with TB disease and 34% for ≥5 children with LTBI annually. We identified substantial variations in the use of interferon-gamma release assays (IGRAs) based upon age, immune status, and TB risk factors. In addition, tuberculin skin test (TST) use was three times more common in younger children. Variations existed in managing children with discordant TST and IGRA results. Less variation existed in LTBI treatment, with 86% preferring a 9-month course of isoniazid; few other, newer regimens were used routinely. CONCLUSION: Substantial variations exist in LTBI management; uptake of newer diagnostic tools and treatment regimens has been slow. Variations in practice and the lag time to integrating new data into practice may indicate the relative infrequency with which providers encounter LTBI. Our findings reflect the need for increased visibility of existing TB guidelines and resources for expert consultation for scenarios not covered by guidelines.

Original languageEnglish (US)
Pages (from-to)1463-1468
Number of pages6
JournalInternational Journal of Tuberculosis and Lung Disease
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

North America
Communicable Diseases
Pediatrics
Infection
Interferon-gamma Release Tests
Tuberculin Test
Skin Tests
Guidelines
Isoniazid
Therapeutics
Referral and Consultation

Keywords

  • Interferon-gamma release assay (IGRA)
  • Practice variation
  • Treatment regimens

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Controversies in tuberculous infection among pediatric infectious disease specialists in North America. / Cruz, A. T.; Hersh, A. L.; Starke, J. R.; Beekmann, S. E.; Polgreen, P. M.; Banerjee, R.

In: International Journal of Tuberculosis and Lung Disease, Vol. 20, No. 11, 01.11.2016, p. 1463-1468.

Research output: Contribution to journalArticle

Cruz, A. T. ; Hersh, A. L. ; Starke, J. R. ; Beekmann, S. E. ; Polgreen, P. M. ; Banerjee, R. / Controversies in tuberculous infection among pediatric infectious disease specialists in North America. In: International Journal of Tuberculosis and Lung Disease. 2016 ; Vol. 20, No. 11. pp. 1463-1468.
@article{a2956e3b366f414a84e9b495b627a9cb,
title = "Controversies in tuberculous infection among pediatric infectious disease specialists in North America",
abstract = "OBJECTIVE: To evaluate the extent to which advancements in the diagnosis and treatment of latent tuberculous infection (LTBI) have been integrated into practice by pediatric infectious disease (PID) specialists. DESIGN: We conducted an online survey of the Infectious Diseases Society of America's Emerging Infections Network (EIN) membership. RESULTS: Of the 323 members, 197 (61{\%}) responded: 7{\%} cared for ≥5 children with TB disease and 34{\%} for ≥5 children with LTBI annually. We identified substantial variations in the use of interferon-gamma release assays (IGRAs) based upon age, immune status, and TB risk factors. In addition, tuberculin skin test (TST) use was three times more common in younger children. Variations existed in managing children with discordant TST and IGRA results. Less variation existed in LTBI treatment, with 86{\%} preferring a 9-month course of isoniazid; few other, newer regimens were used routinely. CONCLUSION: Substantial variations exist in LTBI management; uptake of newer diagnostic tools and treatment regimens has been slow. Variations in practice and the lag time to integrating new data into practice may indicate the relative infrequency with which providers encounter LTBI. Our findings reflect the need for increased visibility of existing TB guidelines and resources for expert consultation for scenarios not covered by guidelines.",
keywords = "Interferon-gamma release assay (IGRA), Practice variation, Treatment regimens",
author = "Cruz, {A. T.} and Hersh, {A. L.} and Starke, {J. R.} and Beekmann, {S. E.} and Polgreen, {P. M.} and R. Banerjee",
year = "2016",
month = "11",
day = "1",
doi = "10.5588/ijtld.16.0366",
language = "English (US)",
volume = "20",
pages = "1463--1468",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "11",

}

TY - JOUR

T1 - Controversies in tuberculous infection among pediatric infectious disease specialists in North America

AU - Cruz, A. T.

AU - Hersh, A. L.

AU - Starke, J. R.

AU - Beekmann, S. E.

AU - Polgreen, P. M.

AU - Banerjee, R.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - OBJECTIVE: To evaluate the extent to which advancements in the diagnosis and treatment of latent tuberculous infection (LTBI) have been integrated into practice by pediatric infectious disease (PID) specialists. DESIGN: We conducted an online survey of the Infectious Diseases Society of America's Emerging Infections Network (EIN) membership. RESULTS: Of the 323 members, 197 (61%) responded: 7% cared for ≥5 children with TB disease and 34% for ≥5 children with LTBI annually. We identified substantial variations in the use of interferon-gamma release assays (IGRAs) based upon age, immune status, and TB risk factors. In addition, tuberculin skin test (TST) use was three times more common in younger children. Variations existed in managing children with discordant TST and IGRA results. Less variation existed in LTBI treatment, with 86% preferring a 9-month course of isoniazid; few other, newer regimens were used routinely. CONCLUSION: Substantial variations exist in LTBI management; uptake of newer diagnostic tools and treatment regimens has been slow. Variations in practice and the lag time to integrating new data into practice may indicate the relative infrequency with which providers encounter LTBI. Our findings reflect the need for increased visibility of existing TB guidelines and resources for expert consultation for scenarios not covered by guidelines.

AB - OBJECTIVE: To evaluate the extent to which advancements in the diagnosis and treatment of latent tuberculous infection (LTBI) have been integrated into practice by pediatric infectious disease (PID) specialists. DESIGN: We conducted an online survey of the Infectious Diseases Society of America's Emerging Infections Network (EIN) membership. RESULTS: Of the 323 members, 197 (61%) responded: 7% cared for ≥5 children with TB disease and 34% for ≥5 children with LTBI annually. We identified substantial variations in the use of interferon-gamma release assays (IGRAs) based upon age, immune status, and TB risk factors. In addition, tuberculin skin test (TST) use was three times more common in younger children. Variations existed in managing children with discordant TST and IGRA results. Less variation existed in LTBI treatment, with 86% preferring a 9-month course of isoniazid; few other, newer regimens were used routinely. CONCLUSION: Substantial variations exist in LTBI management; uptake of newer diagnostic tools and treatment regimens has been slow. Variations in practice and the lag time to integrating new data into practice may indicate the relative infrequency with which providers encounter LTBI. Our findings reflect the need for increased visibility of existing TB guidelines and resources for expert consultation for scenarios not covered by guidelines.

KW - Interferon-gamma release assay (IGRA)

KW - Practice variation

KW - Treatment regimens

UR - http://www.scopus.com/inward/record.url?scp=84992484472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992484472&partnerID=8YFLogxK

U2 - 10.5588/ijtld.16.0366

DO - 10.5588/ijtld.16.0366

M3 - Article

VL - 20

SP - 1463

EP - 1468

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 11

ER -